Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Rexahn Pharmaceuticals starts phase II pancreatic cancer trial

Rexahn Pharmaceuticals, Inc. has announced that it has received FDA approval to begin Phase II trials for Archexin, the Company's leading cancer compound, for the treatment of pancreatic cancer.

24 Mar 2009

Freezing kidney cancer - interventional cryoablation

Freezing kidney tumors - using a safe minimally invasive interventional radiology treatment that kills the cancer 100 percent effectively without surgery - should be the gold standard or first treatment option for all individuals with tumors that are 4 centimeters in size or smaller.

10 Mar 2009

Proepithelin encourages cell growth and migration in prostate cancer

Researchers from Thomas Jefferson University have identified a protein that appears to play a significant role in the growth and migration of prostate cancer cells, especially androgen-independent prostate cancer cells.

26 Feb 2009

Medarex announces allowance of IND application for antibody-drug conjugate, MDX-1203

Medarex, Inc. has announced the allowance of an investigational new drug (IND) application filed with the U.S. Food & Drug Administration (FDA) for MDX-1203, the Company's first Antibody-Drug Conjugate (ADC) candidate generated from its proprietary technology.

29 Jan 2009

New anti-tumor gene called SARI

Researchers from Virginia Commonwealth University have identified a new anti-tumor gene called SARI that can interact with and suppress a key protein that is overexpressed in 90 percent of human cancers.

16 Dec 2008

Antisoma commences phase II trial of AS1411 in metastatic renal cell carcinoma

Cancer drug developer Antisoma plc today announced that it has started a phase II study of AS1411 in metastatic renal cell carcinoma (kidney cancer).

4 Sep 2008

VioQuest Pharmaceuticals issued new U.S. patent for Lenocta

VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.

26 Aug 2008

Cancer Research UK expresses 'deep concern' on kidney cancer drug decision

Cancer Research UK - the largest publicly funded research charity in the UK - wants to see the way NICE review the value of drugs altered for rare diseases, such as this type of kidney cancer, where clinical benefit is proven but evidence is limited.

8 Aug 2008

A paradigm shift for targeted cancer therapy

We already know that recycling benefits our planet; and now new research suggests that the cellular version might be useful for battling cancer.

8 Jul 2008

Discovery of molecule that kills kidney cancer cells

Kidney cancer patients generally have one option for beating their disease: surgery to remove the organ. But that could change, thanks to a new molecule found by Stanford University School of Medicine researchers that kills kidney cancer cells. Ideally, the researchers said, a drug created from this molecule would help fight the life-threatening disease while leaving patients' kidneys intact.

7 Jul 2008

Medarex announces preliminary data for investigational anti-PD-1 antibody

Medarex, Inc. has announced preliminary data from an ongoing Phase 1 study of MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody.

2 Jun 2008

Iron nanoparticles spot tumor spread in patients with kidney cancer

Iron nanoparticles designed to collect in lymph nodes containing metastatic cancer cells have proven that they can help physicians detect metastatic spread of prostate cancer.

18 Apr 2008

Kidney cancer drug attacks a major type of acute myeloid leukemia

A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with acute myeloid leukemia (AML), the most common and lethal form of adult leukemia, researchers at The University of Texas M. D. Anderson Cancer Center report in the Jan. 29 edition of the Journal of the National Cancer Institute.

30 Jan 2008

Wyeth receives European approval for TORISEL

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the European Commission has approved TORISEL (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.

27 Nov 2007

U.S. approval of Nexavar (sorafenib) for inoperable liver cancer

The U.S. Food and Drug Administration has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable.

19 Nov 2007

Reactivating a critical gene lost in kidney cancer reduces tumor growth

Researchers at Mayo Clinic Jacksonville, have found that a key gene is often silenced in clear cell renal cell carcinoma, the most common type of kidney cancer, and when they restored that gene in human kidney cancer cells in culture and animal experiments, tumors stopped growing and many disappeared.

17 Aug 2007

New pathway for inflammation-induced cancer

A well-known inflammatory protein spawns an enzyme that inactivates two tumor-suppressing genes, ultimately triggering production of new blood vessels to nourish breast cancer cells, researchers at The University of Texas M. D. Anderson Cancer Center report in the August edition of the journal Cell .

11 Aug 2007

Interferon alpha and sorafenib combined work better than either alone against kidney cancer

A combination of two drugs works better than either drug alone for patients with renal cell carcinoma, the most common form of kidney cancer, according to a pilot study led by Duke University Comprehensive Cancer Center researchers.

1 Aug 2007

Discovery of method to identify how cancer evades the immune system

One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.

3 Jul 2007

Radio Frequency Ablation emerges as an alternative treatment for inoperable liver cancer

Hollywood talent manager Louis Bershad, 68, whose clients include many top actors in town, recently underwent a routine MRI for kidney stones only to learn from his urologist that he also had a tumor in his left kidney.

26 Jun 2007